RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is an emerging biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer.

The Company’s current product pipeline includes:

RHB-105 - An oral combination therapy for Helicobacter pylori infection, with successful top-line results from a first Phase III study.

RHB-104 - An oral combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway, and for multiple sclerosis, with a Phase IIa proof of concept study underway.

BEKINDA (RHB-102) - A once-daily oral pill formulation of ondansetron, with a Phase III study underway in the U.S. for acute gastroenteritis and gastritis and a Phase II study planed for IBS-D.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

YELIVA (ABC294640) - An orally-administered first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications, with a Phase I/II study initiated for refractory/relapsed diffuse large B-cell lymphoma (DLBCL)

MESUPRON - A Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers.

RP101 -  A Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers, currently subject to an option-to-acquire by RedHill.

RIZAPORT (RHB-103) - An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.